摘要
目的:观察紫杉醇、顺铂、亚叶酸钙及5-氟尿嘧啶联合治疗胃癌的临床疗效及副反应。方法:纳入晚期胃癌患者34例为观察对象,随机分为观察组和对照组各17例,观察组给予紫杉醇(TAx)140mg/m2加入5%葡萄糖注射液或0.9%氯化钠注射液500ml静滴3h,第1、7天各1次;CDDP40mg/m2,静脉滴注并水化,第2~4天;亚叶酸钙(CF)200mg/m2静滴2h,氟尿嘧啶(5-FU)300mg/m2静脉推注后,第2天再1000mg/m2静滴42h。然后停药,21d为1周期,重复给药,3个疗程后观察疗效。对照组除紫杉醇外,其他给药如观察组,周期、疗程同观察组。观察组于治疗前给予抗超敏反应预处理。结果:观察组总有效9例(58.8%)。对照组总有效6例(41.2%)。两组比较差异有显著性意义(P<0.05)。两组不良反应主要包括骨髓抑制、消化道反应、肝脏毒性,无超敏反应,无肾功能损害。两组不良反应差异无显著性意义(P>0.05)。结论:紫杉醇、顺铂、亚叶酸钙及5-氟尿嘧啶联合治疗胃癌是一种非常有效的方法。
Objective:To analyze the curative and side effect about Paclitaxel,DDP, calcium folinate and 5-FU united therapy in the patients suffering from late gastric cancer.Methods:Internalize 34 patients of advanced carcinoma of stomach, tra-bant dividatur 2 groups, therapy group and control group each 17 patients. The therapy group patients were given Paclitaxel 140 mg/m2 mix into 5% GLU or 0.9% NaCl Inj 500 ml IV dr 3h, the 1st day and the 7th day quaque once. CDDP 40 mg/m2,IV drop and hydration. the 2nd day last the 4th day. Calcium:folinate 200 mg/m2 IV dr 2h, 5-FU 1000 mg/m2 IV dr24 h,after 5-FU 300 mg/m2 IV inject, then discontinuation. 21 days as one cycle and three continual cycles as one period of the treatment in both the therapy and control groups.And the control group patients were given the treatment as the therapy group,except paclitaxel. To give the ther-apy group predisposal treatment about anti-hypersensitiveness on pretherapy. Results:In the therapy and control groups the efficiency was 58.8% and 41.2% separately. The significant differences were found between the two groups, P<0.05. The major toxic and side effect were marrow restrain,alimentary canal reactions and hepatotoxicity, no hypersensitiveness and renal functional lesion, these differences were not significant,P>0.05. conclusion Thera-peutic alliance with Paclitaxel,DDP,calcium:folinate and 5-Fu on advanced carcinoma of stomach is an effi cient treatment.
出处
《临床医药实践》
2008年第16期727-729,共3页
Proceeding of Clinical Medicine
关键词
晚期胃癌
紫杉醇
亚叶酸钙
联合治疗
Advanced carcinoma of stomach
Paclitaxel
Calcium folinate
Therapeutic alliance